Optimizing LDL-C: Individualizing Treatment Using Statins and Nonstatin Therapy

Cardiovascular disease (CVD) is the leading cause of death in the United States and a key contributor to CVD is elevated LDL-C levels. AHA and ACC have jointly provided guidelines on how to use ASCVD risk assessment tools to guide decision-making for primary ASCVD prevention. In 2018, an updated AHA/ACC blood cholesterol guideline provided new direction on primary and secondary ASCVD prevention. It included new LDL-C management goals and a discussion of agents that had become FDA-approved after the publication of the 2013 AHA/ACC guidelines. To achieve the AHA’s 2030 impact goal of “equitably increase healthy life expectancy beyond current projections, with global and local collaborators, from 66 years of age to at least 68 years of age across the United States and from 64 years of age to at least 67 years of age worldwide”, clinicians will need to incorporate these new guidelines into clinical practice.

Optimizing LDL-C: Individualizing Treatment Using Statins and Nonstatin Therapy will  review how to use the risk assessment tool, the 2018 LDL-C guidelines recommendations including the role of the non-statin agents ezetimibe and PCSK9 inhibitors. Expert faculty will discuss the role of bempedoic acid, an agent recently approved for LDL-C management, as well as results from trials of inclisiran, an agent in late-stage development.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This activity is supported by educational funding provided by Amgen and Esperion.

Click here for the PCME Privacy Policy